Trade

with

Sangamo BioSciences Inc
(NASDAQ: SGMO)
AdChoices
10.70
+0.18
+1.71%
After Hours :
10.70
0.00
0.00%

Open

10.57

Previous Close

10.52

Volume (Avg)

575.45k (857.33k)

Day's Range

10.43-10.80

52Wk Range

8.93-24.69

Market Cap.

729.36M

Dividend Rate ( Yield )

-

Beta

2.05

Shares Outstanding

68.16M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 24.13M

    • Net Income

    • -26.62M

    • Market Cap.

    • 729.36M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -92.81

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 2.05

    • Forward P/E

    • -82.64

    • Price/Sales

    • 21.32

    • Price/Book Value

    • 3.40

    • Price/Cash flow

    • -196.08

      • EBITDA

      • -26.14M

      • Return on Capital %

      • -17.75

      • Return on Equity %

      • -21.07

      • Return on Assets %

      • -17.75

      • Book Value/Share

      • 3.14

      • Shares Outstanding

      • 68.16M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/17/2014
      Buy
        • 1 Year Price Target

        • 28.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • -0.14

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 49.80

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 8.32

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 82.75

            • Pre-Tax Margin

            • -92.81

            • 39.38

            • Net Profit Margin

            • -92.81

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 100.00

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -152.60

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 12.08

              • 2.92

              • Quick Ratio

              • 11.96

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 1.17

              • 2.21

              • Book Value/Share

              • 3.14

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -22.88

                • 238.10

                • P/E Ratio 5-Year High

                • -53.06

                • 634.30

                • P/E Ratio 5-Year Low

                • -5.07

                • 124.82

                • Price/Sales Ratio

                • 21.28

                • 8.94

                • Price/Book Value

                • 3.39

                • 8.12

                • Price/Cash Flow Ratio

                • -196.08

                • 47.85

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -21.07

                    (-36.00)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -17.75

                    (-30.90)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -21.07

                    (-36.00)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • 0.19

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -26.71M
                  Operating Margin
                  -110.66
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -196.08
                  Ownership

                  Institutional Ownership

                  80.40%

                  Top 10 Institutions

                  44.21%

                  Mutual Fund Ownership

                  32.81%

                  Float

                  96.66%

                  5% / Insider Ownership

                  3.04%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    5,140,407

                  • 0.00

                  • 7.54

                  • Wasatch Small Cap Growth Fund

                  •  

                    1,529,490

                  • -10.28

                  • 2.25

                  • Prudential Jennison Health Sciences

                  •  

                    1,369,675

                  • 0.00

                  • 2.01

                  • SPDR® S&P Biotech ETF

                  •  

                    1,358,672

                  • 0.60

                  • 1.94

                  • iShares Russell 2000 (AU)

                  •  

                    1,067,524

                  • -1.01

                  • 1.53

                  • Vanguard Total Stock Mkt Idx

                  •  

                    1,053,456

                  • 0.00

                  • 1.55

                  • Fidelity Advisor® Biotechnology Fund

                  •  

                    982,368

                  • 0.00

                  • 1.44

                  • iShares Nasdaq Biotechnology

                  •  

                    911,206

                  • 3.08

                  • 1.30

                  • Franklin Biotechnology Discovery

                  •  

                    753,400

                  • 141.63

                  • 1.11

                  • Janus Global Life Sciences Fund

                  •  

                    711,937

                  • 13.52

                  • 1.05

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity Management and Research Company

                  •  

                    6,122,775

                  • 0.00%

                  • 8.99

                  • Wasatch Advisors Inc.

                  •  

                    2,957,946

                  • -5.35%

                  • 4.34

                  • Ridgeback Capital Investments L.p.

                  •  

                    2,900,000

                  • -18.82%

                  • 4.66

                  • RA Capital Management, LLC

                  •  

                    2,791,305

                  • -46.55%

                  • 4.10

                  • Adage Capital Partners Gp LLC

                  •  

                    2,550,000

                  • -8.93%

                  • 3.74

                  • BlackRock Fund Advisors

                  •  

                    2,306,932

                  • -12.34%

                  • 3.39

                  • Frontier Capital Management CO Inc

                  •  

                    2,222,395

                  • +68.72%

                  • 3.26

                  • State Street Corp

                  •  

                    2,120,350

                  • +11.51%

                  • 3.11

                  • Vanguard Group, Inc.

                  •  

                    2,016,481

                  • +2.95%

                  • 2.96

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Classic Growth

                  Style

                  Small Growth

                  Sangamo BioSciences Inc was incorporated in June 1995 in the state of Delaware. It is a clinical stage biopharmaceutical that company engaged in the research, development and commercialization of engineered DNA-binding proteins for t...morehe development of novel therapeutic strategies for unmet medical needs. The Company is engaged in the development of novel human therapeutics and is building a pipeline of ZFP Therapeutics. Its ZFP Therapeutic, SB-728-T, a ZFN-modified autologous T-cell product for the treatment of HIV/AIDS, is the first therapeutic application of its ZFN technology and is being evaluated in an ongoing Phase 2 and two Phase 1/2 clinical trials. It has preclinical ZFP Therapeutic development programs in hemophilia and Parkinsons disease. In addition, it has research stage programs in othe...morer monogenic diseases; genetic conditions that result from a defect in a single gene, including hemoglobinopathies such as sickle cell anemia, lysosomal storage diseases and certain immunodeficiencies. On 8 January 2014, the Company has a collaborative partnership with Biogen Idec Inc.to research, develop and commercialize our preclinical ZFP Therapeutic development program, in hemoglobinopathies, and targeting sickle cell disease (SCD) and beta-thalassemia. It has a license agreement with the research reagent company Sigma-Aldrich Corporation (Sigma). Sigma has the exclusive rights to develop and market high value laboratory research reagents based upon its ZFP technology as well as ZFP-modified cell lines for commercial production of protein pharmaceuticals and ZFP-engineered transgenic animals. Sigma is marketing ZFN-derived gene editing tools under the trademark CompoZr and is selling transgenic animals through its SAGETM Labs business unit. The Company has a license agreement with Dow AgroSciences, LLC (DAS), a wholly owned subsidiary of Dow Chemical Corporation. Under the agreement, it has provided DAS with access to its ZFP technology and the exclusive rights to use it to modify the genomes or alter the nucleic acid or protein expression of plant cells, plants, or plant cell cultures. DAS markets its ZFN technology under the trademark EXZACTTM Precision Technology. The Company has retained rights to use plants or plant-derived products to deliver ZFP TFs or ZFNs into human or animals for diagnostic, therapeutic, or prophylactic purposes. It faces competition from other companies for collaborative arrangements with pharmaceutical and biotechnology companies; for establishing relationships with academic and research institutions; and for licenses to proprietary technology. Its therapeutic or pharmaceutical products undergoes rigorous preclinical testing and clinical trials in humans and an extensive regulatory clearance process implemented by the U.S. Food and Drug Administration (FDA) under the federal Food, Drug and Cosmetic Act.lessless

                  Key People

                  Edward O. Lanphier,II

                  Founder/CEO/President/Director

                  William R. Ringo,Jr

                  Chairman of the Board/Director

                  H. Ward Wolff

                  CFO/Chief Accounting Officer/Executive VP

                  Dr. Geoffrey M. Nichol

                  Executive VP, Divisional

                  Dr. Dale G. Ando,M.D.

                  Chief Medical Officer/Vice President, Divisional

                  • Sangamo BioSciences Inc

                  • 501 Canal Boulevard

                  • Richmond, CA 94804

                  • USA.Map

                  • Phone: +1 510 970-6000

                  • Fax: +1 510 236-8951

                  • sangamo.com

                  Incorporated

                  1995

                  Employees

                  85

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: